CLDN18.2 expression

News alerts, weekly reports and conference planners

Entrez ID:

51208

Related biomarkers:

Expression

Fusion

‹

›

Related tests:

VENTANA CLDN18 (43-14A) Assay (2)

CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 expression	Esophageal Adenocarcinoma	CLDN18.2 expression	Esophageal Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastric Adenocarcinoma	CLDN18.2 expression	Gastric Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Lung Cancer	CLDN18.2 expression	Lung Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Esophageal Cancer	CLDN18.2 expression	Esophageal Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3
CLDN18.2 expression	Gastroesophageal Cancer	CLDN18.2 expression	Gastroesophageal Cancer	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	CT041 Sensitive: C4 – Case Studies CT041 Sensitive : C4	CT041 Sensitive: C4 – Case Studies CT041 Sensitive : C4
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
CLDN18.2 expression	Lung Adenocarcinoma	CLDN18.2 expression	Lung Adenocarcinoma	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Colon Cancer	CLDN18.2 expression	Colon Cancer	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Hepatocellular Cancer	CLDN18.2 expression	Hepatocellular Cancer	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Endometrial Cancer	CLDN18.2 expression	Endometrial Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D
CLDN18.2 expression	Ovarian Cancer	CLDN18.2 expression	Ovarian Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D

CLDN18.2 expression

Associations